267 related articles for article (PubMed ID: 25153725)
1. Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells.
Gray GK; McFarland BC; Rowse AL; Gibson SA; Benveniste EN
Oncotarget; 2014 Aug; 5(15):6484-96. PubMed ID: 25153725
[TBL] [Abstract][Full Text] [Related]
2. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.
Zheng Y; McFarland BC; Drygin D; Yu H; Bellis SL; Kim H; Bredel M; Benveniste EN
Clin Cancer Res; 2013 Dec; 19(23):6484-94. PubMed ID: 24036851
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy.
Ruggeri E; Frezzato F; Mouawad N; Pizzi M; Scarmozzino F; Capasso G; Trimarco V; Quotti Tubi L; Cellini A; Cavarretta CA; Ruocco V; Serafin A; Angotzi F; Danesin N; Manni S; Facco M; Piazza F; Trentin L; Visentin A
Front Immunol; 2024; 15():1393485. PubMed ID: 38807597
[TBL] [Abstract][Full Text] [Related]
4. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Interactions of 5-Fluorouracil with Inhibitors of Protein Kinase CK2 Correlate with p38 MAPK Activation and FAK Inhibition in the Triple-Negative Breast Cancer Cell Line.
Wińska P; Karatsai O; Staniszewska M; Koronkiewicz M; Chojnacki K; Rędowicz MJ
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872257
[TBL] [Abstract][Full Text] [Related]
6. Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer.
Romieu-Mourez R; Landesman-Bollag E; Seldin DC; Traish AM; Mercurio F; Sonenshein GE
Cancer Res; 2001 May; 61(9):3810-8. PubMed ID: 11325857
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells.
Romieu-Mourez R; Landesman-Bollag E; Seldin DC; Sonenshein GE
Cancer Res; 2002 Nov; 62(22):6770-8. PubMed ID: 12438279
[TBL] [Abstract][Full Text] [Related]
8. Protein Kinase CK2 Controls the Fate between Th17 Cell and Regulatory T Cell Differentiation.
Gibson SA; Yang W; Yan Z; Liu Y; Rowse AL; Weinmann AS; Qin H; Benveniste EN
J Immunol; 2017 Jun; 198(11):4244-4254. PubMed ID: 28468969
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase CK2 is involved in zinc homeostasis in breast and prostate cancer cells.
Zaman MS; Johnson AJ; Petersingham G; Muench GW; Dong Q; Wu MJ
Biometals; 2019 Dec; 32(6):861-873. PubMed ID: 31583500
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.
Manni S; Brancalion A; Mandato E; Tubi LQ; Colpo A; Pizzi M; Cappellesso R; Zaffino F; Di Maggio SA; Cabrelle A; Marino F; Zambello R; Trentin L; Adami F; Gurrieri C; Semenzato G; Piazza F
PLoS One; 2013; 8(9):e75280. PubMed ID: 24086494
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
12. CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells.
Silva-Pavez E; Villar P; Trigo C; Caamaño E; Niechi I; Pérez P; Muñoz JP; Aguayo F; Burzio VA; Varas-Godoy M; Castro AF; Colombo MI; Tapia JC
Cell Death Dis; 2019 Jan; 10(2):73. PubMed ID: 30683840
[TBL] [Abstract][Full Text] [Related]
13. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
[TBL] [Abstract][Full Text] [Related]
14. Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells.
Eddy SF; Guo S; Demicco EG; Romieu-Mourez R; Landesman-Bollag E; Seldin DC; Sonenshein GE
Cancer Res; 2005 Dec; 65(24):11375-83. PubMed ID: 16357145
[TBL] [Abstract][Full Text] [Related]
15. Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.
Pizzi M; Piazza F; Agostinelli C; Fuligni F; Benvenuti P; Mandato E; Casellato A; Rugge M; Semenzato G; Pileri SA
Oncotarget; 2015 Mar; 6(9):6544-52. PubMed ID: 25788269
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia.
Quotti Tubi L; Canovas Nunes S; Brancalion A; Doriguzzi Breatta E; Manni S; Mandato E; Zaffino F; Macaccaro P; Carrino M; Gianesin K; Trentin L; Binotto G; Zambello R; Semenzato G; Gurrieri C; Piazza F
Leukemia; 2017 Feb; 31(2):292-300. PubMed ID: 27479180
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.
Quotti Tubi L; Gurrieri C; Brancalion A; Bonaldi L; Bertorelle R; Manni S; Pavan L; Lessi F; Zambello R; Trentin L; Adami F; Ruzzene M; Pinna LA; Semenzato G; Piazza F
J Hematol Oncol; 2013 Oct; 6():78. PubMed ID: 24283803
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Rice WG; Ryckman DM; Anderes K
Mol Cell Biochem; 2011 Oct; 356(1-2):37-43. PubMed ID: 21755459
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition.
Dixit D; Sharma V; Ghosh S; Mehta VS; Sen E
Cell Death Dis; 2012 Feb; 3(2):e271. PubMed ID: 22318540
[TBL] [Abstract][Full Text] [Related]
20. Effect of Simultaneous Inhibition of Protein Kinase CK2 and Thymidylate Synthase in Leukemia and Breast Cancer Cells.
Wińska P; Skierka K; Łukowska-Chojnacka E; Koronkiewicz M; Cieśla J; Bretner M
Anticancer Res; 2018 Aug; 38(8):4617-4627. PubMed ID: 30061228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
